EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 387 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug April 23, 2018 New on NCI’s Websites, March 2020 March 16, 2020 Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 August 20, 2020 Patient Guide in Testicular Cancer Now Available Also in German January 14, 2026 Load more HOT NEWS What to Know About Peer-Reviewed Cancer Information and Its Role in... Can Chemotherapy Drugs Be Designed to Avoid Side Effects? FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... Osteoblasts Are “Warrior” Bone Cells That Can Suppress Bone-Metastatic Breast Cancer...
